Glenn M. Chertow
Publication Details
-
Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl.
Kidney Int. 2005; (2): 760-71
The National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (NKF-K/DOQItrade mark) has established guidelines for treatment of secondary hyperparathyroidism (HPT). The ability of cinacalcet HCl (Sensipartrade mark) treatment to improve achievement of target levels of parathyroid hormone (PTH), calcium, phosphorus, and calcium-phosphorus product (Ca x P) was investigated in subjects on dialysis with secondary HPT.
Help